All In Biotech

Drug Trial Radar · NCT06429761

Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients

Aprospective, Multi Center Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, an Anti-her2-antibody Drug Conjugate in Indian Patients With Unresectable or Metastatic her2-positive Breast Cancer Who Have Received a Prior Anti-her2-based Regimen

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

100

Actual

Start

Jan 2, 2025

Primary completion

Oct 31, 2026

Study completion Oct 31, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
May 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A PROSPECTIVE, MULTI-CENTER, PHASE 4, SINGLE ARM STUDY TO ASSESS THE SAFETY OF TRASTUZUMAB DERUXTECAN, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE IN INDIAN PATIENTS WITH UNRESECTABLE OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED A PRIOR ANTI-HER2-BASED REGIMEN

Conditions

  • BREAST CANCER

Interventions

  • Trastuzumab deruxtecanDrug

    IV infusion Trastuzumab deruxtecan will be administered at 5.4 mg/kg on day 1 of a 21 day cycle for 9 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the safety of trastuzumab deruxtecan in adult Indian patientsTime frame: 6 Months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Bangalore, India

  • Research Site

    Delhi, India

  • Research Site

    Kochi, India

  • Research Site

    Mumbai, India

  • Research Site

    New Delhi, India

  • Research Site

    Pune, India

  • Research Site

    Varanasi, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.